ArticleFuture medicinal chemistry2026
Neurotransmitter & precursor to the neurotransmitter linked lawsone derivatives: design, synthesis, molecular docking, and evaluation of antidiabetic potential.
Article in Future medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsType 2 diabetes mellitus (T2DM) is an increasingly prevalent worldwide health problem, and new antidiabetic agents are needed to address the limitations of current therapies. The research aims to create and assess hybrid compounds based on lawsone that contain neurochemical frameworks as potential agents for treating T2DM. PATIENTS AND METHODS/MATERIALS AND
methodsHydroxy naphthoquinone-based hybrids were synthesized using dopamine and tryptophan and characterized by spectral techniques. Density Functional Theory (DFT/B3LYP) calculations were performed to analyze molecular geometry, electrostatic potential, and spectral properties. Antioxidant activity was assessed for reactive oxygen species (ROS) scavenging. Drug-likeness was predicted using SwissADME. Molecular docking was conducted against α-amylase (PDB: 4W93) and α-glucosidase (PDB: 2ZE0), followed by
resultsHybrids demonstrated impressive antioxidant properties as well as acceptable pharmacokinetics. Using docking studies, it is clear that hybrids bind stably to the active sites of enzymes based on important interactive forces. Additionally, both hybrids were found to inhibit α-amylase and α-glucosidase
conclusionsHybrids that are derived from lawsone show promise for being multifunctional agents for treating diabetes, and they should be evaluated further in preclinical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.